Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials

ESC Heart Failure

Volumn 4, Issue 4, 2017, Pages 595-604

  Silvetti, Simona ^a   Belletti, Alessandro ^a   Fontana, Antonella ^b   Pollesello, Piero ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b ORION CORPORATION   (Finland)

Author keywords

Advanced heart failure; Intermittent; Levosimendan; Meta analysis; Rehospitalization; Repetitive

Indexed keywords

HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; VASODILATOR AGENT;

CAUSE OF DEATH; DOSE RESPONSE; DRUG ADMINISTRATION; GLOBAL HEALTH; HEART FAILURE; HOSPITAL READMISSION; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TRENDS;

CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLOBAL HEALTH; HEART FAILURE; HUMANS; HYDRAZONES; PATIENT READMISSION; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; VASODILATOR AGENTS;

EID: 85049530582     PISSN: None     EISSN: 20555822     Source Type: Journal    
DOI: 10.1002/ehf2.12177     Document Type: Article

References (33)

1. Altenberger J, Parissis JT, Costard-Jaeckle A, Winter A, Ebner C, Karavidas A, Sihorsch K, Avgeropoulou E, Weber T, Dimopoulos L, Ulmer H, Poelzl G. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail 2014; 16: 898–906.
2. Nieminen MS, Altenberger J, Ben-Gal T, Böhmer A, Comin-Colet J, Dickstein K, Edes I, Fedele F, Fonseca C, García-González MJ, Giannakoulas G, Iakobishvili Z, Jääskeläinen P, Karavidas A, Kettner J, Kivikko M, Lund LH, Matskeplishvili ST, Metra M, Morandi F, Oliva F, Parkhomenko A, Parissis J, Pollesello P, Pölzl G, Schwinger RH, Segovia J, Seidel M, Vrtovec B, Wikström G. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. Int J Cardiol 2014; 15: 360–367.
3. Silvetti S, Greco T, Di Prima AL. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials. Clin Res Cardiol 2014; 103: 505–513.
4. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M, SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297: 1883–1891.
5. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Någren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. J Clin Pharmacol Ther 1997; 61: 596–607.
6. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Någren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during levosimendan infusion in congestive heart failure. J Clin Pharmacol Ther 2000; 68: 522–531.
7. Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F. A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 2005; 34: 224–225.
8. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
9. Greco T, Zangrillo A, Biondi-Zoccai G, Landoni G. Meta-analysis: pitfalls and hints. Heart Lung Vessel 2013; 5: 219–225.
10. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. http://handbook.cochrane.org/ (2 February 2017).
11. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6 e1000100.
13. Mavrogeni S, Giamouzis G, Papadopoulou E, Thomopoulou S, Dritsas A, Athanasopoulos G, Adreanides E, Vassiliadis I, Spargias K, Panagiotakos D, Cokkinos DV. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail 2007; 13: 556–559.
14. Kleber FX, Bollmann T, Borst MM, Costard-Jäckle A, Ewert R, Kivikko M, Petterson T, Pohjanjousi P, Sonntag S, Wikström G. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol 2009; 49: 109–115.
15. Bonios MJ, Terrovitis JV, Drakos SG, Katsaros F, Pantsios C, Nanas SN, Kanakakis J, Alexopoulos G, Toumanidis S, Anastasiou-Nana M, Nanas JN. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol 2012; 159: 225–229.
16. Malfatto G, Della Rosa F, Villani A, Rella V, Branzi G, Facchini M, Parati G. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance and one-year survival. J Cardiovasc Pharmacol 2012; 60: 450–455.
17. Comin-Colet J, on behalf of the LION Heart Study Investigators. Multicenter, double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of intermittent levosimendan in outpatients with advanced chronic heart failure: the LION Heart study. Paper presented at the European Society of Cardiology–Heart Failure Association Congress, Seville, Spain, 24 May, 2015. https://spo.escardio.org/SessionDetails.aspx?eevtid=1077&sessId=14858&subSessId=0&searchQuery=%2fdefault.aspx%3feevtid%3d1077%26days%3d%26topics%3d%26types%3d%26rooms%3d%26freetext%3dcomin-colet%26sort%3d1%26page%3d1%26showResults%3dTrue%26nbPerPage%3d20%26WithWebcast%3d%26WithSlides%3d%26WithAbstract%3d%26WithReport%3d%26scroll%3D456#.WT4tn7h_S3o (15 May 2017).
18. García-González MJ, on behalf of the LAICA Study Investigators. Efficacy and security of intermittent repeated levosimendan administration in patients with advanced heart failure: a randomized, double-blind, placebo controlled multicenter trial: LAICA study. Paper presented at the European Society of Cardiology–Heart Failure Association Congress, Florence, Italy, 21 May, 2016. https://spo.escardio.org//SessionDetails.aspx?eevtid=1126&presId=136186&doc=Webcast#.WT4sdrh_S3o (15 May 2017).
19. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81–86.
20. García-González MJ, de Mora-Martín M, López-Fernández S, López-Díaz J, Martínez-Sellés M, Romero-García J, Cordero M, Lara-Padrón A, Marrero-Rodríguez F, del Mar García-Saiz M, Aldea-Perona A, LAICA study investigators. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study. Cardiovasc Drugs Ther 2013; 27: 573–579.
21. Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012 Feb; 40: 634–646.
22. Nieminen MS, Dickstein K, Fonseca C, Serrano JM, Parissis J, Fedele F, Wikström G, Agostoni P, Atar S, Baholli L, Brito D, Colet JC, Édes I, Gómez Mesa JE, Gorjup V, Garza EH, González Juanatey JR, Karanovic N, Karavidas A, Katsytadze I, Kivikko M, Matskeplishvili S, Merkely B, Morandi F, Novoa A, Oliva F, Ostadal P, Pereira-Barretto A, Pollesello P, Rudiger A, Schwinger RH, Wieser M, Yavelov I, Zymliński R. The patient perspective: quality of life in advanced heart failure with frequent hospitalisations. Int J Cardiol 2015; 191: 256–264.
23. Fruhwald S, Pollesello P, Fruhwald F. Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations. Expert Rev Cardiovasc Ther 2016; 14: 1335–1347.
24. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005; 96: 11G–17G.
25. Mills RM. The heart failure frequent flyer: an urban legend. Clin Cardiol 2009; 32: 67–68.
26. Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation 2012; 126: 501–506.
27. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP, Heart Failure Clinical Research Network NHLBI. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016; 316: 500–508.
28. Mushtaq S, Andreini D, Farina S, Salvioni E, Pontone G, Sciomer S, Volpato V, Agostoni P. Levosimendan improves exercise performance in patients with advanced chronic heart failure. ESC Heart Fail. 2015; 2: 133–141.
29. Teerlink JR, Felker GM, McMurray JJ, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JG, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM, ATOMIC-AHF Investigators. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study. J Am Coll Cardiol. 2016; 67: 1444–1455.
30. Packer M, O'Connor C, McMurray JJ, Wittes J, Abraham WT, Anker SD, Dickstein K, Filippatos G, Holcomb R, Krum H, Maggioni AP, Mebazaa A, Peacock WF, Petrie MC, Ponikowski P, Ruschitzka F, van Veldhuisen DJ, Kowarski LS, Schactman M, Holzmeister J, TRUE-AHF Investigators. N Engl J Med. 2017; 376: 1956–1964.
31. Teerlink JR, on behalf of the RELAX-AHF-2 Study Investigators. RELAX-AHF-2: Serelaxin in acute heart failure. Presentation at the ESC Heart Failure congress 2017, Paris. http://spo.escardio.org/SessionDetails.aspx?eevtid=1226&sessId=20859&subSessId=0&searchQuery=%2fdefault.aspx%3feevtid%3d1226%26days%3d%26topics%3d%26types%3d%26rooms%3d%26freetext%3dmetra%26sort%3d1%26page%3d1%26showResults%3dTrue%26nbPerPage%3d20%26WithWebcast%3d%26WithSlides%3d%26WithAbstract%3d%26WithReport%3d%26scroll%3D228#WRv5CTHkW3E (May 15 2017).
32. Blecker S, Ladapo JA, Doran KM, Goldfeld KS, Katz S. Emergency department visits for heart failure and subsequent hospitalization or observation unit admission. Am Heart J. 2014; 168: 901–908.
33. Ayodele L, Rudnika-Noulin D. Heart Failure Epidemiology. LLC: Decision Resources Group publisher; 2016.